ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Dana-Farber Correction Plan Sent To State; Pharmacy Chief Resigns

June 9, 1995

NCI Cooperative Group Clinical Trials Listed

April 24, 2009

Aranesp Study Finds No Difference In Survival Or Progression In Small-Cell Lung Cancer.

April 20, 2007

M. D. Anderson Buys Record System For In-Patient Services From Atlanta Firm.

May 4, 2001

In Brief: Charles Heidelberger, Sol Spiegelman Both Die of Cancer; Robert Wittes New CTEP Director

January 28, 1983

NIH Alternative Medicine Officer Under Fire For Proposed RFA In Homeopathy, Acupuncture

February 26, 1993